Precision Medicine in Oncology®

HER2 status in patients with breast cancer has emerged as a durable and effective marker for evaluating tumors and selecting therapies.

Researchers are reporting better survival rates in women with invasive EOC and germline mutations in the tumor suppressor genes BRCA1 and BRCA2 than in patients who are noncarriers.

Dr. Neil Spector, from the Duke Cancer Institute, Discusses the Complexities of Cancer

Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses ABC DLBCL Research

The MET signaling network has emerged as an important target for cancer therapy, with a particularly significant role in controlling the cancer hallmarks of metastasis and angiogenesis.

Dr. Jenny Chang, from the Methodist Cancer Center, Discusses Combining HER2 Targeted Therapies

The Massachusetts General Hospital (MGH) Cancer Center comprises 23 fully integrated, multidisciplinary clinical programs, as well as an extensive array of support and educational services.

Jill M. Siegfried, PhD, is an investigator into the role of growth factors and hormones in the development and growth of lung cancer.

It is always difficult to distinguish what may legitimately be considered disease flare from the more likely scenario of the events simply representing the natural history of the malignancy.

The DDIs between Co-Rx medications and targeted OAD is associated with a significant decrease in effectiveness and increased toxicity.

Dr. Roman Perez-Soler, from Albert Einstein College of Medicine, on the Future of Lung Cancer Therapies

Clarient provides more than 350 diagnostic tests to assess and characterize tumors, including tests for BRAF, KRAS, and EGFR gene mutations.

Dr. Chandra Belani from Penn State Hershey Cancer Institute Discusses Driver Mutations in NSCLC

Dr. Sridhar Ramaswamy from the Massachusetts General Hospital Cancer Center Discusses Tumor Heterogeneity

Patients who initially exhibit a response to a particular strategy may achieve substantial clinical benefit if the same or very similar agents are delivered after variably defined treatment-free intervals.

Dr. Brian Leyland-Jones from Winship Cancer Institute Discusses Genome Sequencing

Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting

Year after year, the John Theurer Cancer Center (JTCC) harnesses the newest technologies and retains world-class oncologists, nurses, and scientists to fulfill its mission of delivering extraordinary care to patients in the community.

Dr. Sridhar Ramaswamy, from Massachusetts General Hospital Cancer Center, on Dormant Tumor Cells and Resistance

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the Stratification of Clinical Trials

Dr. Jose Baselga, from Massachusetts General Hospital, Describes the Basis Behind the BOLERO-2 Trial

Dr. Ezra Cohen, from University of Chicago, on mTOR Inhibition in Head and Neck Cancer

Dr. Sridhar Ramaswamy, from Massachusetts General Hospital Cancer Center, on Targeting Dormant Cancer Cells

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses Targeting the mTOR Pathway

Dr. Deirdre Cohen, from NYU Medical Oncology Associates, Addresses the Role of the Hedgehog Pathway